CoChat
Sign Up
Cited by 200Breast Cancer Treatment StudiesEstrogen and related hormone effectsAdvanced Breast Cancer Therapies

American Society of Clinical Oncology Technology Assessment on the Use of Aromatase Inhibitors as Adjuvant Therapy for Women With Hormone Receptor–Positive Breast Cancer: Status Report 2002

Winer, Eric P., Hudis, Clifford, Burstein, Harold J., Chlebowski, Rowan T., Ingle, James N., Edge, Stephen B., Mamounas, Eleftherios P., Gralow, Julie +9 more·2002·Journal of Clinical Oncology
DOI 10.1200/jco.2002.06.020
Open this paper in CoChat — free account

Abstract

OBJECTIVE: To conduct an evidence-based technology assessment to determine whether the routine use of anastrozole or any of the aromatase inhibitors in the adjuvant breast cancer setting is appropriate for broad-based conventional use in clinical practice. POTENTIAL INTERVENTIONS: Anastrozole, letrozole, and exemestane. OUTCOMES: Outcomes of interest include breast cancer incidence, breast cancer-specific survival, overall survival, and net health benefit. EVIDENCE: A comprehensive, formal literature review was conducted for relevant topics and is detailed in the text. Testimony was collected from invited experts and interested parties. The American Society of Clinical Oncology (ASCO)-prescribed technology assessment procedure was followed. BENEFITS/HARMS: The ASCO panel recognizes that a woman and her physician's decision regarding adjuvant hormonal therapy is complex and will depend on the importance and weight attributed to information regarding both cancer and non-cancer-related risks and benefits. CONCLUSION: The panel was influenced by the compelling, extensive, and long-term data available on tamoxifen. Overall, the panel considers the results of the Arimidex (anastrozole) or Tamoxifen Alone or in Combination (ATAC) trial and the extensive supporting data to be very promising but insufficient to change the standard practice at this time (May 2002). A 5-year course of adjuvant tamoxifen remains the standard therapy for women with hormone receptor-positive breast cancer. The panel recommends that physicians discuss the available information with patients, and, in making a decision, acknowledge that treatment approaches can change over time. Individual health care providers and their patients will need to come to their own conclusions, with careful consideration of all of the available data. (Specific questions addressed by the panel are summarized in Appendix 3.) VALIDATION: The conclusions of the panel were endorsed by the ASCO Health Services Research Committee and the ASCO Board of Directors.

Integrity signals

Registry

Crossref · 10.1200/jco.2002.06.020

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Anastrozole and letrozole are selective aromatase inhibitors; they are reversible and highly potent.

    “Anastrozole and letrozole are selective aromatase inhibitors.They are reversible and highly potent.”

    From A new era in ovulation induction (2006) · cites this paper as [34]

  • At doses of 1-5 mg, anastrozole and letrozole decrease E levels by 97%-99%.

    “Their intrinsic potency is considerably greater than that of aminoglutethimide, and at doses of 1-5 mg decreases E levels by 97%-Ͼ99%.”

    From A new era in ovulation induction (2006) · cites this paper as [34]

  • Letrozole and anastrazole are completely absorbed after oral administration, with a mean half-life of approximately 45 hours (range, 30-60 hours).

    “Letrozole and anastrazole are completely absorbed after oral administration, with a mean half-life of approximately 45 hours (range, 30 -60 hours).”

    From A new era in ovulation induction (2006) · cites this paper as [34]

  • Aromatase inhibitors are orally administered, easy to use, and relatively inexpensive, with minor side effects.

    “They are orally administered, easy to use, and relatively inexpensive, with minor side effects.”

    From A new era in ovulation induction (2006) · cites this paper as [34]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Winer, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., Braun, S., Cobleigh, M. A., Langer, A. S., Perotti, J., Powles, T. J., Whelan, T. J., & Browman, G. P.
Affiliations
American Society of Clinical Oncology (US)
ORCID
Venue
Journal of Clinical Oncology
Publisher
American Society of Clinical Oncology (ASCO)
Published
2002-08-01
Volume
20
Issue
15
Pages
3317-3327
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
DOI
10.1200/jco.2002.06.020
OpenAlex
W4236627566
Cited by
200
References
36
Citations by year
2024: 1 · 2023: 1 · 2022: 6 · 2020: 3 · 2019: 5 · 2018: 1 · 2017: 5 · 2016: 6 · 2015: 5 · 2014: 6 · 2013: 4 · 2012: 5
FWCI
2.16
Type
journal article
Language
en
Open access
closed
Locations
  • Journal of Clinical Oncology (publishedVersion)
  • PubMed (publishedVersion)
Funders
American Society of Clinical Oncology
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Estrogen and related hormone effects
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Advanced Breast Cancer Therapies
Keywords
aromatase inhibitors, adjuvant therapy, hormone receptor-positive breast cancer, anastrozole, letrozole, exemestane, tamoxifen, breast cancer-specific survival, overall survival, net health benefit, ATAC trial, risk-benefit decision-making
MeSH terms
Anastrozole, Breast Neoplasms, Enzyme Inhibitors, Expert Testimony, Female, Humans, Nitriles, Tamoxifen, Triazoles, Survival Analysis, Randomized Controlled Trials as Topic, Chemotherapy, Adjuvant, Postmenopause, Disease-Free Survival, Antineoplastic Agents, Hormonal, Evidence-Based Medicine, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review